Dr. Al-Katib is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
19229 Mack Ave
Suite 34
Grosse Pointe Woods, MI 48236Phone+1 313-647-3245Fax+1 313-647-3244
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1980 - 1983
- University of Mosul College of MedicineClass of 1974
Certifications & Licensure
- NY State Medical License 1982 - Present
- MI State Medical License 1985 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Most Compassionate Doctor American Registry
- Super Doctor SuperDoctors.com
Clinical Trials
- Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 1997 Jan 01
- Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Start of enrollment: 1996 Dec 01
- Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 1998 May 01
- Join now to see all
Publications & Presentations
PubMed
- 19 citationsTargeting CD19 in B-cell lymphoma: emerging role of SAR3419Ali Raufi, Abdul Shukkur Ebrahim, Ayad Al-Katib
Cancer Management and Research. 2013-08-27 - 12 citationsEstablishment and characterization of a human lymphoma cell line (WSU-NHL) with 14;18 translocationAnwar N. Mohamed, Ayad Al-Katib
Leukemia Research. 1988-01-01 - 26 citationsNon-Hodgkin's lymphoma: an analysis of the Metropolitan Detroit SEER database.Mary Varterasian, John J. Graff, Richard K. Severson, Linda K. Weiss, Ayad Al-Katib
Cancer Investigation. 2000-01-01
Lectures
- A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-HodgkinÍs Lymphoma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Isolation and Characterization of a CD34+ Sub-Clone in B-Cell Lymphoma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Grant Support
- Phase II Trial Of Bryostatin 1 And 2-CDA In Relapsed CLLNational Cancer Institute1997–1998
- Phase II Evaluation Of Bryostatin 1 In Lymphoma And CLLNational Cancer Institute1997–1998
- Differentiation Related Proteins In Malignant CellsNational Cancer Institute1994
- Differentiation-Related Proteins In Malignant CellsNational Cancer Institute1990–1993
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: